CVS Health Corporation reported strong fourth-quarter 2024 earnings, with adjusted earnings per share (EPS) of $1.19 surpassing estimates of $0.93, despite a year-over-year decline from $2.12. Revenue increased by 4.2% year-over-year to $97.71 billion, beating expectations of $97.19 billion. Same-store sales rose by 10.2%, exceeding the estimated 7.71%. The Pharmacy and Consumer Wellness segment led growth with a 7.5% revenue increase, achieving a record high prescription market share of 27.3%. The Health Care Benefits segment's revenue reached $32.96 billion, and the Medical Loss Ratio improved to 94.8%, better than the expected 95.9%. CVS Health projected operating cash flow of approximately $6.5 billion for fiscal year 2025 and provided an adjusted EPS guidance between $5.75 and $6.00. Following the earnings announcement, CVS Health's stock surged by over 15%, marking its best one-day gain since October 1999.